NCT06829199 2026-02-19
MK-5890-003
Merck Sharp & Dohme LLC
Phase 2 Withdrawn
Clinical Trials
15 trialsNCT06291064 2026-02-17
TARMAC
University of Chicago
Phase 2 Recruiting
NCT07320508 2026-01-21
EIC-SNACC
Eye & ENT Hospital of Fudan University
Phase 2 Recruiting
NCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
NCT04872985 2026-01-06
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT06107673 2025-12-11
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT04214626 2025-11-19
R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Completed
NCT07016399 2025-10-30
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT03515798 2025-09-12
PELICAN
Institut Paoli-Calmettes
Phase 2 Active not recruiting
NCT04138719 2025-09-11
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT06860529 2025-06-23
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT01630083 2025-06-15
FAST
Astellas Pharma Inc
Phase 2 Completed
NCT06964906 2025-05-11
NeoHunter
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT04668365 2025-04-25
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Suspended